Arbutus Biopharma (NASDAQ:ABUS) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.

Several other equities analysts also recently weighed in on ABUS. BidaskClub raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. Leerink Swann reissued a “market perform” rating and set a $5.00 target price (up previously from $4.00) on shares of Arbutus Biopharma in a research report on Tuesday, November 7th. Finally, B. Riley assumed coverage on Arbutus Biopharma in a research report on Friday, January 5th. They set a “buy” rating and a $10.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Arbutus Biopharma presently has a consensus rating of “Hold” and an average price target of $12.50.

Shares of Arbutus Biopharma (NASDAQ ABUS) opened at $5.05 on Friday. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 12 month low of $2.45 and a 12 month high of $8.25. The stock has a market capitalization of $278.01, a P/E ratio of -1.01 and a beta of 1.07.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.21. The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $0.79 million. sell-side analysts expect that Arbutus Biopharma will post -1.26 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Arbutus Biopharma by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Arbutus Biopharma by 16.6% during the 4th quarter. Victory Capital Management Inc. now owns 150,720 shares of the biopharmaceutical company’s stock valued at $761,000 after purchasing an additional 21,460 shares during the last quarter. OxFORD Asset Management LLP increased its position in shares of Arbutus Biopharma by 89.9% during the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 39,436 shares during the last quarter. RTW Investments LP increased its position in shares of Arbutus Biopharma by 1.1% during the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Arbutus Biopharma in the 3rd quarter valued at $1,393,000. 60.00% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/valuengine-upgrades-arbutus-biopharma-abus-to-sell/1838032.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.